Cymabay Therapeu Performance
CBAYDelisted Stock | USD 11.83 0.27 2.34% |
The firm shows a Beta (market volatility) of -1.38, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Cymabay Therapeu are expected to decrease by larger amounts. On the other hand, during market turmoil, Cymabay Therapeu is expected to outperform it. Cymabay Therapeu right now shows a risk of 0.0%. Please confirm Cymabay Therapeu downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if Cymabay Therapeu will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cymabay Therapeu has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Cymabay Therapeu is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Begin Period Cash Flow | 20.3 M |
Cymabay |
Cymabay Therapeu Relative Risk vs. Return Landscape
If you would invest 1,183 in Cymabay Therapeu on October 11, 2024 and sell it today you would earn a total of 0.00 from holding Cymabay Therapeu or generate 0.0% return on investment over 90 days. Cymabay Therapeu is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Cymabay, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Cymabay Therapeu Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cymabay Therapeu's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cymabay Therapeu, and traders can use it to determine the average amount a Cymabay Therapeu's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
CBAY |
Based on monthly moving average Cymabay Therapeu is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cymabay Therapeu by adding Cymabay Therapeu to a well-diversified portfolio.
Cymabay Therapeu Fundamentals Growth
Cymabay Stock prices reflect investors' perceptions of the future prospects and financial health of Cymabay Therapeu, and Cymabay Therapeu fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cymabay Stock performance.
Return On Equity | -0.64 | |||
Return On Asset | -0.22 | |||
Operating Margin | (745.58) % | |||
Current Valuation | 3.45 B | |||
Shares Outstanding | 114.78 M | |||
Price To Earning | (8.62) X | |||
Price To Book | 12.76 X | |||
Price To Sales | 119.98 X | |||
Revenue | 31.07 M | |||
EBITDA | (101 M) | |||
Cash And Equivalents | 153.42 M | |||
Cash Per Share | 1.81 X | |||
Total Debt | 114.49 M | |||
Debt To Equity | 1.45 % | |||
Book Value Per Share | 2.57 X | |||
Cash Flow From Operations | (72.53 M) | |||
Earnings Per Share | (0.99) X | |||
Total Asset | 434.69 M | |||
Retained Earnings | (978.23 M) | |||
Current Asset | 42.79 M | |||
Current Liabilities | 6.15 M | |||
About Cymabay Therapeu Performance
Evaluating Cymabay Therapeu's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Cymabay Therapeu has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cymabay Therapeu has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. Cymabay Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.Things to note about Cymabay Therapeu performance evaluation
Checking the ongoing alerts about Cymabay Therapeu for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cymabay Therapeu help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Cymabay Therapeu is not yet fully synchronised with the market data | |
Cymabay Therapeu has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 31.07 M. Net Loss for the year was (105.37 M) with loss before overhead, payroll, taxes, and interest of (41.63 M). | |
Cymabay Therapeu currently holds about 153.42 M in cash with (72.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81. | |
Over 99.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Cymabay Therapeu's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cymabay Therapeu's stock is overvalued or undervalued compared to its peers.
- Examining Cymabay Therapeu's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cymabay Therapeu's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cymabay Therapeu's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cymabay Therapeu's stock. These opinions can provide insight into Cymabay Therapeu's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Cymabay Stock
If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Stocks Directory Find actively traded stocks across global markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |